Andy Billinton

Andy Billinton has a long and varied work experience. Andy began their career in 1998 as a Post-Doctoral Research Assistant at The Babraham Institute, where they explored cognitive performance in preclinical models. In 2001, they joined GlaxoSmithKline as an Associate Director in Pain Neurosciences, leading role in pain drug discovery biology from idea to Phase 2a Proof of Concept. Andy then moved to Transpharmation Ltd. in 2010 as Director of Translational Biology and Operations. From 2011 to 2019, they worked at AstraZeneca as Senior Director of Neuroscience Innovative Medicines and Early Development and Director of Neuroscience Innovative Medicines. In 2019, they joined NodThera Limited as Senior Director of Therapeutics and Translational Science. Most recently, they are the Chief Scientific Officer at Transine Therapeutics, a position they have held since 2022.

Andy Billinton obtained a BSc in Pharmacology from the University of Bristol between 1991 and 1994. Andy then went on to pursue a PhD in Neuroscience at the University of Birmingham, which they completed in 1998.